Abstract
Pembro showed durable antitumor activity and manageable safety for treatment of advanced UC in the first-line (1L) setting for cisplatin-ineligible pts (phase 2 KEYNOTE-052 study [NCT02335424]) and second-line (2L) setting for platinum-refractory pts (phase 3 KEYNOTE-045 study [NCT02256436]). This exploratory analysis evaluated if results for East Asian pts are consistent with global results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
